FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington,	D.C.	20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL									
OMB Number: 3235-028									
Estimated average burden									
hours per response:	0.5								

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b)

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

(Last)	Marc (F LECTIN THACHTREE OSS G.	HERAPEUTICS INDUSTRIAL A		ΓΕ 240 —	3. E 03/	Issuer Name and Ticker or Trading Symbol GALECTIN THERAPEUTICS INC GALT 3. Date of Earliest Transaction (Month/Day/Year) 03/25/2021 4. If Amendment, Date of Original Filed (Month/Day/Year)							CT (Cr	Relationship of Reporting Person(s) to Issuer Check all applicable) X Director 10% Owner Officer (give title below) Individual or Joint/Group Filing (Check Applicable ine) X Form filed by One Reporting Person Form filed by More than One Reporting Person				
1. Title of Security (Instr. 3) 2. Trans Date					action Day/Ye	1			3. Transac Code (I 8)	ction nstr.	(4) or			or 5. Amount of		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)		7. Nature of Indirect Beneficial Ownership (Instr. 4)
(e.g., p 1. Title of 2. 3. Transaction Date Secution Date, Texture of Execution Date, Texture of Exec			uts, ransac	sts, calls, warrants,			uired, Disposed of, or Bene c, options, convertible secul 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and of Securiti Underlying Derivative (Instr. 3 an			rities) d Amount es	8. Price of Derivative Security (Instr. 5)	9. Number derivative Securities Beneficial Owned Following Reported Transactic (Instr. 4)	ly	Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	Beneficial Ownership (Instr. 4)			
				c	Code	v	(A)	(D)	Date Exercisab		xpiration ate	Title	Amount or Number of Shares					
Stock option (right to buy) ⁽¹⁾	\$2.11	03/25/2021			A		40,000		(2)	0	3/25/2031	Common Stock	40,000	\$0.00	40,000)	D	
Stock option (right to buy) ⁽¹⁾	\$2.11	03/25/2021			A		70,000		(3)	0	3/25/2031	Common Stock	70,000	\$0.00	70,000)	D	

Explanation of Responses:

- 1. The options were issued pursuant to the Galectin Therapeutics Inc. 2019 Omnibus Equity Incentive Plan.
- 2. Such options vest 100% on March 31, 2022.
- 3. Such options vest when (i) the Company has received the interim results of its NAVIGATE clinical trial and (ii) makes a public announcement that it has received the interim results.

Remarks:

(1) The reporting person is president and director of Ed Uihlein Family Foundation, a not-for-profit corporation. The reporting person has no pecuniary interest in the shares, however, he shares voting and dispositive power over the shares and, therefore, remains the beneficial owner of the shares solely for the purposes of Section 13(d) of the Securities Exchange Act of 1934.

/s/ Jack W. Callicutt, by power 03/29/2021 of attorney

** Signature of Reporting Person

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.